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Abstract
It is becoming increasingly clear that the soluble protofibrillar species that proceed amyloid fibril formation are associated
with a range of neurodegenerative disorders such as Alzheimer’s and Parkinson diseases. Computer simulations of the
processes that lead to the formation of these oligomeric species are starting to make significant contributions to our
understanding of the determinants of protein aggregation. We simulate different systems at constant concentration but
with a different number of peptides and we study the how the finite number of proteins affects the underlying free energy
of the system and therefore the relative stability of the species involved in the process. If not taken into account, this finite
size effect can undermine the validity of theoretical predictions regarding the relative stability of the species involved and
the rates of conversion from one to the other. We discuss the reasons that give rise to this finite size effect form both a
probabilistic and energy fluctuations point of view and also how this problem can be dealt by a finite size scaling analysis.
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Introduction
A major field of study in protein science is the understanding of
the causes, and implications of protein aggregation. The misfold-
ing of proteins often results in aggregates and in the formation of
highly regular structures called amyloid fibrils [1–3]. Amyloids are
best known for their involvement in pathological conditions such
as type II diabetes systemic amyloidosis and neurodegenerative
disorders such as Alzheimer’s, Parkinson’s and Creutzfeldt-Jakob
diseases [3–7]. Increasing evidence is showing that indeed it is the
soluble pre-fibrillar or oligomeric species, rather than the insoluble
amyloid fibrils themselves, which are responsible for toxicity and
neuronal disfunction [8–10]. Even if highly complex processes are
associated with oligomer toxicity, a view is gaining support
according to which the ability to form toxic oligomeric species
represents an intrinsic property of polypeptide chains at some
stage of their oligomerization process [8,10]. Despite this growing
interest in the role of peptide and protein oligomers in disease, the
molecular mechanism by which they are formed is still the object
of investigation of several in vivo, in vitro, and in silico studies [4,11–
19]. However, since it is challenging to describe the early stages of
aggregation of polypeptide chains experimentally, primarily
because of the difficulties in detecting and characterising the
small, structurally heterogeneous and transient species that are
involved, a detailed description of this process at the molecular
level remains in large part elusive. In particular the heterogeneous
nature of these species implies that their free energy landscape is
very rugged. Theoretical studies are starting to make important
contributions to the understanding of these diseases by investigat-
ing the partially unfolded intermediates and the structural features
of the oligomeric species [15,16,18,20–24].
Due to limitations in computers power, simulations are usually
performed in the NVT ensemble on systems ranging form a couple
of peptides with detailed all atom models to several hundred with
very coarse grained models [15–35]. We will discuss how these
studies can be affected by the finite size effect and how this has
repercussions on the underlying free energy of the system. This is
indeed a major difference between in silico and in vitro studies, as in
the latter the number of proteins is in the order of the Avogadro
number. This effect has been studied in the case of proteins of
different lengths [36]. In the following we will discuss in detail the
finite size effect specifically in the case of simulations of protein
aggregation and we will underline some strategies to deal with it.
Results
Free Energy Calculations in Systems with Different Sizes
We study how the actual number of proteins or peptides in our
simulation, irrespectively of their concentration, affects the
underlying free energy landscape of the system. In particular we
investigate six systems of three, four, six, eight, nine and twelve
‘‘Gly-Phe-Phe’’ (GFF) peptides at constant concentration and for
eight different temperatures using the parallel tempering technique
and with periodic boundary conditions (see Methods). A similar
peptide (Phe-Phe), was studied experimentally by the group of
Gazit [37] and it was found to form nanotube-like structures. We
choose however to add a Gly to the peptide to increase its
propensity to form inter-peptide hydrogen bonding.
For each system we calculate the free energy as a function of the
inter-chain hydrogen bond interaction energy normalised over the
number of peptides for each different temperature used in the
parallel tempering. In this way we can monitor the formation and
stability of the aggregated state alone. Our computationally
efficient Monte Carlo sampling allow us to calculate easily the
free energy landscape for systems up to twelve GFF peptides. In
Fig 1, Fig 2, and Fig 3 we plot such landscapes and we can notice
how in each system the aggregated state becomes more stable as
the temperature decreases and how by increasing system size the
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The influence of the number of particles on the free energy of the
system for a given concentration can be explained by the following
example. If we consider a system where all N proteins are
aggregated (e.g. N=3 in Fig 4, left) the probability of another
protein to be added to the oligomer is zero simply because there
are no monomers left. For this given set of conditions (temperature
and concentration), therefore, the proteins in the aggregated state
Figure 1. Free Energy landscape as a function of inter chain hydrogen bond energy for a system of 3 peptides for temperatures
ranging from T=0.588 to T=0.322. In the lower right corner we show a characteristic oligomeric configuration at T=0.322.
doi:10.1371/journal.pone.0002641.g001
Figure 2. Free Energy landscape as a function of inter chain hydrogen bond energy for a system of 6 peptides for temperatures
ranging from T=0.588 to T=0.322. In the lower right corner we show a characteristic oligomeric configuration at T=0.322. By comparing the
free energy profile for T=0.4 in the present and in Fig: 1, we can notice the increase in stability of the aggregated phase that results by simply
increasing the number of peptide in the system and the volume of the system so that the concentration remains constant.
doi:10.1371/journal.pone.0002641.g002
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proteins and the volume of the system are increased so that the
concentration in unchanged (Fig 5 right) the probability of the
proteins in the oligomers to go back in solution is the same as before
but this time the probability of the aggregate to growis also different
from zero, because there is one more monomer left in the solution.
Asa result thestabilityoftheoligomerofsizeN isincreased.Inother
words, by increasing the number of proteins for a given
concentration and temperature, the free energy barrier between
the monomeric and the aggregated phases also increases and the
stability of the aggregates increases as we can see for example from
comparing the free energy at T=0.4 in Figs 1 and 2.
Another reason for this change in stability is related to the
change in the relative size of the fluctuations of the energy of the
system. Being the energy an extensive quantity its expectation
value (mean) is proportional to the number of particles in the
system while its root mean square fluctuations (standard deviation)
are proportional only to the square root of that number.
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In small systems therefore, this ratio is not negligible, so the
energy fluctuations can destabilise the system, while a system with
large N having more degrees of freedom, has also more ways to
absorb the energy and therefore its fluctuations are smaller. Small
Figure 3. Free Energy landscape as a function of inter chain hydrogen bond energy for a system of 12 peptides for temperatures
ranging from T=0.588 to T=0.322. In the lower right corner we show a characteristic oligomeric configuration at T=0.322.
doi:10.1371/journal.pone.0002641.g003
Figure 4. Schematic change in the probability of aggregation
in two systems with different number of proteins. If the proteins
in the system are all aggregated (left) the stability of an oligomer
formed by three proteins is limited by the probability of one protein to
go back in solution. In another system (right) both the number of
proteins and the volume are increased so that the concentration is left
unchanged but since there is one monomer still in solution that can
potentially aggregate, the stability of the oligomer is increased.
doi:10.1371/journal.pone.0002641.g004
Figure 5. Finite size scaling analysis. We fitted the average internal
energy in each system to the equation: e(N)=e‘+AN
a and we plotted
the results as a function of N
20.82, where 20.82 is the value of a
obtained from the fit using all our available data.
doi:10.1371/journal.pone.0002641.g005
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their aggregated phase changes consequently. This latter effect
should be expected to be smaller for larger proteins [36] in which
the large number of amino acids (degrees of freedom) will reduce,
already in the monomer, the energy fluctuations. Indeed this
would also be the case if the simulations are performed in explicit
solvent as the number of degrees of freedom is increased and
therefore the energy fluctuations become smaller.
Finite Size Scaling
In Fig 5 we discuss the finite size analysis to this problem. This
type of analysis is commonly used to estimate the typical systematic
errors introduced by the finite size of the system on the calculation
of various observables. The analysis starts by simulating systems of
different sizes at equilibrium and calculating an observable (e.g. the
internal energy). Following the procedure used in [38], we fit the
average internal energy per peptide with an equation of the form:
e(N)=e‘+AN
a, where e‘ is the asymptotic value of the internal
energy for infinite systems, N is the system size (i.e. the number of
peptides or proteins used in the simulation) and a is the scaling
exponent. For this particular example we do not have estimates for
e‘ and a, as was the case in [38], therefore we fit all three
parameters to the average internal energy calculated for the lowest
temperature, T=0.322, in which we know from our free energy
profiles that the peptides are aggregated. Since we have three
parameters to fit with only 6 points, our estimates will not be very
reliable so by fitting our equation to all possible combinations of
5 points we obtain a rough estimate of their range of validity:
212.5#e‘#29.5, 0.01#A#0.05, 21.1#a#20.6. These values
are obviously too broad and a more precise estimate, in particular
of the exponent a, should be obtained, either by using a more
coarse grained model that will allow simulations of large systems,
or by an explicit analytical calculation. In Fig 5 we plot our data
along with the best fit over the entire set of data as a function of
N
20.82, where 20.82 is the value of a taken from this fit. Future
work will be required to understand more deeply the precise
nature of the exponent a, particularly to understand if it belongs to
the class of critical exponents [39] and has therefore a high degree of
universality i.e. its value is constant for a class of different proteins
having similar characteristics.
Discussion
In the present paper we have discussed the how the number of
protein present in the system, if small, influences the underlying
free energy and therefore shifts the equilibrium between the
different species. We have discussed two independent causes of this
problem; the first being that the stability of an oligomer is related
to the number of monomers or other oligomers still present in the
system, the second related to the relative fluctuations of the system
being proportional to N
21/2.
The presence of this finite size effect has very important
implications for the in silico studies of protein aggregation, e.g. it is
the reason why usually the protein concentration in these studies is
taken to be much larger than the concentration used in the
corresponding in vitro studies and, more importantly, implies the
presence of a systematic error in every estimate of the stability or
the rate of formation of one specific aggregate configuration. A
way to deal with these problems is to perform a finite size scaling
analysis. This type of analysis allows to correct one observable (as
we did for the internal energy in section ‘‘Finite Size Scaling’’) for
the systematic error introduced by the finite size of the system. We
have outlined how this analysis works, how to carry it out, and we
have estimated the values of the parameters within a small range.
A more precise estimate of these parameters would be needed and
to this end a coarse grained model should be employed to be able
to study a much larger number of peptides and to obtain a precise
estimate of the parameters of the scaling analysis. More work will
also be required to investigate the degree of universality of such
analysis i.e. whether a class of proteins with similar characteristics
have the same critical exponent [39]. If verified this would
represent a leap forward in our understanding of the generic
physical properties of protein aggregation. The theory behind
critical exponents was object of intensive studies in physics in
between the 1964–1976. Nowadays, at least from a physical point
of view the problem is essentially solved, although in many cases
only approximate solutions are available.
Some biological problems require, however, the use of models
with a detailed geometrical representation [15,18,20,23,40]. The
use of these models makes the finite scaling analysis computation-
ally very difficult, particularly for the study of large systems of
medium or large peptides. In these cases a special care should be
taken in the interpretation of the theoretical results. A useful
approach is the one we have taken in a recent study [40] where we
calculated the free energy as a function of the b-sheet size for two
systems of 20 and 30 Ab25–35 peptides, under the same conditions
of temperature and concentration. A comparison between the free
energy of the two systems allowed us to estimate up to which point
our calculations were reliable, and the trend of the errors on the free
energy due to the finite size effect. Understanding in detail the
systematic error induced by the finite size effect in simulations of
aggregation is becoming an issue of the utmost importance as
theoretical studies are becoming more precise and their descrip-
tion of the process is becoming more quantitative. We believe
therefore, that the results that we have presented in the present
study and the results of [36] represent a very important initial step
towards the formulation of a more general theory of finite size
scaling for protein aggregation.
Methods
Simulations were carried out with ProFASi (Protein Folding and
Aggregation Simulator) [41], which implements an implicit water
all-atom model [41–45] for protein folding and aggregation
studies. The model assumes fixed bond lengths, bond angles, and
peptide torsional angles, so that each amino acid has only has the
Ramachandran torsional angles and the side chains torsional
angles as its degrees of freedom. The interaction potential
E~EloczEevzEhbzEhp ð1Þ
is composed of four terms. The Eloc term is local and represents an
electrostatic interaction between adjacent peptides along the chain
and the Eev term is an 1/r
12 repulsion between pairs of atoms. The
hydrogen bonding contributions to the energy are calculated by a
term, Ehb, in which the distance dependence is modelled through a
Lennard-Jones potential between pairs of NH and C’O groups
within a given cutoff of 4.5 A ˚, and the angular dependence is
expressed as a function of the NH    O and H    OC0 angles.
The hydrogen bonds between the backbone NH (C’O) groups and
the C’O (NH) groups on each side of them are disallowed. The GFF
peptide used in this study, therefore, does not form intra-chain
hydrogen bonds and the hydrogen bonding term of the energy
monitors only the formation of intra-chain hydrogen bonds. The
hydrophobicity term Ehp is defined by a contact potential between
hydrophobic side chains, the latter being proportional to the
fraction of atoms in contact in the two amino acids. The
parameters of the potential were chosen by optimizing the
Finite Size Effect
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protein; the resulting force field has been shown to reproduce
accurately the folded states and the melting temperatures of a
range of polypeptide chains of both a and b structures, including
Betanova, GB1p, LLM and Fs, with excellent agreement with both
CD and NMR data. In addition, properties such as the content of
a-helix and the relative population of folded species was also found
to be in excellent agreement with experimental data. ProFASi has
also already been applied to study the aggregation of a series of
short peptides, including the Ab16–22 and Ab25–35 peptides
[15,30,40]. We performed simulations of six systems composed
of three, four, six, eight, nine and twelve GFF three-peptides, using
the parallel tempering technique [46–47] using 8 temperatures
ranging from T=0.322 to T=0.588 (Fig 1, Fig 2 and Fig 3). We
choose not to map the Monte Carlo temperature in Kelvin units as
was done by Irba ¨ck and co-workers [42] for the folding of small
peptides because in the case of aggregation being the underlying
free energy changed due to the finite size effect, it should be tested
experimentally whether any such mapping still holds true. The
simulations were performed in a cubic box with periodic boundary
conditions of sizes respectively: 20, 22.01 25.2, 27.72, 28.84 and
31,74 A ˚. We changed the volume for different for systems with
different number of peptides so to keep the concentration constant.
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